Anyone know anything about this, do we, SSTY, own it:
February 23, 2007 - 8:45 AM EST
Biofield Successfully Demonstrates its Technology to Leading Physicians, Officials, and Healthcare Providers in Mexico City
PHILADELPHIA, Feb. 23 /PRNewswire-FirstCall/ -- Biofield Corp. (OTC Bulletin Board: BZET) announced that on January 10-12, 2007, it successfully conducted patient demonstrations and seminars of its patented breast cancer diagnostic device in Mexico City before more than 50 OB/GYN and other physicians, nurses, officials, and representatives from leading hospitals, clinics, laboratories, pharmaceutical companies, and other health providers based in Mexico and other countries in Latin America. The demonstrations and seminars were conducted by a noted physician in Mexico City with Biofield representatives from the US and Mexico on female patients with pre-confirmed malignant and benign tumors. Biofield's device tested successfully in the patient demonstrations, generating substantial interest among Mexican OBY/GYN and healthcare communities. The purpose of the demonstrations and seminars was to introduce Biofield's technology to leading opinion makers in the Mexican healthcare community and to seek to secure purchase orders for the device and sensors. Subsequent meetings and discussions have taken place with leading hospitals, clinics, physicians, and other opinion leaders in Mexico, many of which also have clinics, stores, or other facilities in other Latin American countries. Presentations of Biofield's technology were also made on Mexican TV.
Biofield Chairman, James MacKay, stated: 'When I acquired Biofield, it was my hope to bring its life-saving technology overseas, especially Asia, in line with the vision and legacy of Biofield's prior Chairman, Dr. David Long. While we may have appeared to be quiet lately, we have been busy on many fronts building the foundations needed to penetrate China, the Philippines, and other parts of Asia. With the interest generated from the Mexico demonstrations, we are now building the foundation to serve the sizeable female population in Latin America. Biofield also intends to benefit from the leading technologies of TPID and Globe Staff. To protect against the health risks associated with counterfeit medical equipment, Biofield intends to use TPID's leading anti-counterfeiting technology on its devices and sensors. Because the device is portable and intended to reach women via mobile units wherever they are, not just major medical centers, Biofield also intends to use Globe Staff's leading geo-tracking technology on its devices.'
Chairman MacKay continued: 'Our initiatives into Asia and Latin America are important both from a medical and market perspective. Because it is cost effective, portable, non-invasive, and radiation and compression-free, can be operated by personnel with only a few days training, and shows results in approximately 15 minutes, our device is well suited for both developing and developed countries. The market for our sensors is also ideal. In Asia and Latin America, there are approximately 1.1 billion women 15-64 years old with China's and Mexico's numbers over 418 and 35 million respectively. Each Biofield test requires a new set of 18 sensors, which are discarded after each test. Depending on test results, a woman may undergo several tests per year.'
About Biofield Corp.
Biofield Corp., a medical technology company, engages in the development and provision of noninvasive diagnostic medical devices to assist in detecting breast cancer. It offers Biofield Diagnostic System, a breast cancer diagnostic device, which employs single-use sensors to measure and analyze changes in cellular electrical charge distributions associated with the development of epithelial cancers, such as breast, ovaries, skin, prostate, and colon cancers. The company's device is intended for palpable breast lesions, in women under 55 years of age. For more information, go to biofield.com.
About True Product ID
True Product ID produces integrators for anti-counterfeiting and security surveillance applications and is a provider of integrated tracking devices. The Company delivers turnkey solutions for governments, armed forces, and industry, through its own proprietary technology and through aggregating the technology, products, and services of third parties via licensing agreements and or joint ventures. For more information about True Product ID, Inc. and Chinese joint venture, True Product ID Technology (Beijing) Limited, go to: tpid.net and trueproductid.com.
About Globe Staff Consulting Corporation and Sure Trace Security Corporation
Globe Staff Consulting Corporation is a subsidiary of Sure Trace Security Corporation (OTC: SSTY). Globe was formed for the purpose of selling and distributing wireless security communications services and is focusing on tracking, tracing and geolocalization of products and people. The company has developed a mix of security tracking services targeting businesses, governments and consumers. Our technology assists our customers to be informed in real time of the exact location of products or people, with 2way communication and can be customized to meet additional client requirements. Globe's innovative product and service offerings provide the best advantages to customers, including the smallest tracking modules with GSM and GPS dual capability and innovative specialty cellular phone models, data capability, all hosted on an ASP server platform. Sure Trace specializes in acquiring and incubating new and varied technologies. For more information go to: suretrace.com and gsc.fr.
SAFE HARBOR STATEMENT: Certain statements made in this press release should be considered forward-looking and subject to various risks and uncertainties. Such forward-looking statements are based on management's belief, as well as assumptions made by, and information currently available to, management pursuant to the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements can generally be identified as such because the context of the statement will include words such as 'believes,' 'anticipates,' 'appears,' 'expects,' 'should,' 'may,' or words of similar import. Similarly, statements that describe the company's future plans, objectives, estimates or goals are also forward-looking statements. Such statements may address future events and conditions concerning, among other matters, (i) the ability of the company to obtain sufficient funding in order to maintain operations, complete its FDA application and have its equipment manufactured and (ii) the granting of approval by the FDA of the company's Breast Proliferation Detection System, which may not occur or, if it does, may not be timely. Additional factors which should be considered are set forth in the company's Annual Report on Form 10-KSB and Quarterly Report on Form 10-QSB. Copies of such documents can be obtained from the EDGAR database Internet web site maintained by the Securities and Exchange Commission at sec.gov. The company undertakes no obligation to release publicly the results of any revisions to its forward-looking statements that may be made in this press release to reflect events or circumstances occurring after the date of this press release.
CONTACT:
Biofield Corp.
Michael Yom, President
myom@biofield.com
215.972.1717
|
